MPMatthew Bryan Potts

Matthew Bryan Potts

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Matthew Bryan Potts has a total of 192 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Correction: Schupp et al. Deconstructing Intratumoral Heterogeneity through Multiomic and Multiscale Analysis of Serial Sections. Cancers 2024, 16, 2429

    by Patrick G. Schupp, Samuel J. Shelton, Daniel J. Brody, Rebecca Eliscu, Brett E. Johnson, Tali Mazor, Kevin W. Kelley, Matthew B. Potts, Michael W. McDermott, Eric J. Huang, et al.

  • Modeling interhospital stroke transfers for endovascular treatment in the four largest cities in the USA

    by Nicholas Besley, Joshua M Tennyson, Fan Z Caprio, Matthew B Potts

    Background Interhospital transfers of stroke patients to higher levels of care for endovascular treatment (EVT) are common. Optimizing transfer times may help improve overall reperfusion times. We sought to model and compare the ground travel times for health system-affiliated and nearest EVT-capable stroke center transfers and examine associated factors in the four largest cities in the USA: New York City (NYC), Los Angeles (LA), Chicago, and Houston. Methods We identified EVT-capable centers (defined as comprehensive, thrombectomy-capable, and primary plus stroke centers) and their health system-affiliated hospitals for each city. For each affiliated hospital, we used a Monte Carlo simulation to model ambulance travel times to its system EVT-capable center as well as the nearest EVT-capable center. We subsequently analyzed hospital service area variables associated with prolonged (extra travel time to affiliated hospital >20 min) transfers. Results The total travel time (mean (SD), min) to an affiliated versus nearest EVT-capable center was 29.9 (10.2) versus 14.4 (2.0) (PConclusion This study characterized theoretical stroke transfer networks in the four largest US cities and showed that affiliated-hospital system transfers may increase overall transfer times compared with transferring to the nearest EVT-capable center.

  • Biomarkers of Thromboelastography Platelet Mapping Predict Hematoma Expansion After Spontaneous Intracerebral Hemorrhage

    by Kaleigh M. Copenhaver, Juliana Silva Pinheiro Do Nascimiento, Rajeev K. Garg, Fernando D. Goldenberg, Harish Shownkeen, Matthew B. Potts, Babak S. Jahromi, Paul F. Lindholm, Andrew M. Naidech

    BACKGROUND: Hematoma expansion (HE) is a preventable cause of disability and death in patients with acute intracerebral hemorrhage (ICH). Platelet activity is essential for coagulation, and antiplatelet medications (eg, aspirin, clopidogrel) increase HE risk. General markers of platelet activity are associated with later HE, but specific biomarkers of platelet activity could enhance our understanding. We hypothesized that hemostatic biomarkers of platelet activity would correlate with later HE. METHODS: We conducted a tri-center observational cohort study of spontaneous ICH patients with multiple imaging scans for HE calculation. The thromboelastography 6s Platelet Mapping assay assessed platelet activity with 3 biomarkers: (1) adenosine diphosphate receptor-induced platelet activation, (2) platelet-fibrin network clot strength measured by heparinized kaolin with heparinase, and (3) fibrinogen-only clot strength measured by activator F (ActF). Spearman rank measured the correlation between HE and platelet activity. A linear regression model predicted HE from ActF. We tested whether the relationship between ActF and HE interacted with pre-ICH antiplatelet medication. RESULTS: Thirty-five patients were included. Eleven (35.48%) took pre-ICH antiplatelet medication. Heparinized kaolin with heparinase negatively correlated with HE ( ρ =−0.34, P =0.02), indicating that stronger platelet-fibrin clots were associated with less subsequent HE. ActF’s association with HE depended on pre-ICH antiplatelet medication use (interaction P =0.005). More ActF (fibrinogen) was associated with less HE in patients who did not take pre-ICH antiplatelet medication. CONCLUSIONS: Hemostatic biomarkers from the thromboelastography 6s Platelet Mapping assay predicted subsequent HE and may aid in determining neurosurgical need. Strengthening platelet-mediated coagulation may be a target for reducing HE and improving ICH outcomes.


  • Bilateral middle meningeal artery embolization for the treatment of bilateral chronic subdural hematoma

    by Rahul K. Chaliparambil, William Metcalf-Doetsch, Babak S. Jahromi, Matthew B. Potts


  • Middle Meningeal Artery Embolization for Chronic Subdural Hematoma: A Bibliometric Analysis

    by Rahul K. Chaliparambil, Babak S. Jahromi, William Metcalf-Doetsch, Matthew B. Potts


  • Neuroanatomy of the vertebrobasilar perforators: implications for aneurysm treatment

    by Eytan Raz, Maksim Shapiro, Erez Nossek, Daniel H Sahlein, Matthew B Potts, Vera Sharashidze, Charlotte Chung, Caleb Rutledge, Ayaz Mahmood Khawaja, Howard A Riina, et al.

    The anatomy of vertebrobasilar perforators has been widely studied in human cadavers, with most reports found in the neurosurgical literature. These arterial perforators are extremely hard to visualize consistently with traditional two-dimensional digital subtraction angiography, but are reliably visible with cross sectional cone beam CT techniques. A clear understanding of this specific neurovascular anatomy and pathology is essential for informed treatment decisions. This review analyzes the anatomy of vertebrobasilar perforators with a focus on practical implications for aneurysm treatment, particularly flow diversion.


  • Laparoscopic-Assisted Peritoneal Access in Ventriculoperitoneal Shunt Placement: Systematic Review and Meta-Analysis

    by Sunny Abdelmageed, Prottusha Sarkar, Nathan A. Shlobin, Daniel G. Davila, Matthew B. Potts

    BACKGROUND AND OBJECTIVES: The most common treatment of hydrocephalus is ventriculoperitoneal (VP) shunting. Peritoneal access is commonly conducted through an open laparotomy, but laparoscopic peritoneal access is gaining popularity. Many studies have reported the benefits of minimally invasive laparoscopic peritoneal access, but there is no consensus on its use. We conducted a systematic review and meta-analysis to compare open laparotomy vs laparoscopic peritoneal access in VP shunting. METHODS: A systematic search was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines using 3 databases. Twelve studies included only adults, 3 included only pediatric patients, and 3 included both adults and pediatric patients. RESULTS: Compared with open laparotomy, laparoscopic peritoneal access was associated with a reduction in distal shunt failure (6.1% vs 2.2%, P = .01), operative time (69.4 vs 56.3 minutes, P < .001), and length of stay (LOS) (9.6 vs 7.3 days, P < .001). There were no differences in proximal shunt failure, total shunt failure, intraoperative complications, or infection rate. In the pediatric population, laparoscopic access was associated with a reduced LOS (7.8 vs 5.9 days, P < .001). Heterogeneity was high but explained by the varying study populations and techniques. CONCLUSION: Laparoscopic peritoneal access for VP shunt insertion is associated with improved outcomes, including reduced distal shunt failure, reduced operative time, and reduced hospital LOS, when compared with open laparotomy and should be considered for shunt insertion. Additional studies are necessary to further determine the benefit of laparoscopic access, especially in the pediatric population.


  • Volume-staged versus dose-staged stereotactic radiosurgery, with or without embolization, in the treatment of large brain arteriovenous malformations: A systematic review and meta-analysis

    by Collin J. Larkin, Zachary A. Abecassis, Ketan Yerneni, Dominic A. Nistal, Constantine L. Karras, Pedram Golnari, Matthew B. Potts, Babak S. Jahromi


  • Safety of Postembolization Antithrombotic Therapy After Middle Meningeal Artery Embolization

    by Rahul K. Chaliparambil, Mykhaylo Krushelnytskyy, Khizar R. Nandoliya, Shreya Mukherjee, Babak S. Jahromi, William Metcalf-Doetsch, Matthew B. Potts

    BACKGROUND AND OBJECTIVES: Middle meningeal artery embolization (MMAE) for the management of chronic subdural hematoma (cSDH) has been suggested as a preferred treatment in patients where reinitiating antithrombotic (AT) therapy is necessary. In this study, we evaluate whether reinitiating AT therapy before cSDH resolution after MMAE affects radiographic and clinical resolution. METHODS: This is a retrospective study of patients who underwent MMAE at our institution between 2018 and 2024. Clinical and radiographic findings were analyzed with standard statistical approaches. Kaplan-Meier curves for nonresolution compared AT and no-AT groups and compared AT resumption before and after 30 days after surgery. RESULTS: In 111 MMAE procedures, the median age was 73 years, 27.9% were female, and 80.6% were White. The median follow-up was 5.1 months. Forty-six patients (41.4%) demonstrated complete resolution of their cSDH. Eleven patients (9.9%) had reoperation after MMAE. The median cSDH depth was 14.0 mm, and the median midline shift was 3.0 mm. Thirty-two patients (28.8%) resumed AT before resolution. The median time to resumption was 35.5 days. Patients in the AT group were less likely to have radiographic resolution (21.9% vs 49.4%, odds ratios = 0.2872, 95% CI = 0.1113-0.7404, P = .0103) but comparable rates of reoperation and residual symptomatic presentations. Resumption of AT therapy before or after 30 days from surgery had no effects on outcome measures on univariate analysis. Major outcomes were similar between patients receiving antiplatelet-only or anticoagulant-only medications. CONCLUSION: Reinitiating AT therapy before cSDH resolution was associated with decreased rates of resolution, but comparable rates of reoperation and residual symptoms. Our results support the cautious reinitiation of AT therapy in patients requiring it after MMAE.